Skip to Content

Sunosi (solriamfetol) Disease Interactions

There are 3 disease interactions with Sunosi (solriamfetol):


Solriamfetol (applies to Sunosi) cardiovascular toxicities

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Heart Disease

Solriamfetol increases systolic blood pressure, diastolic blood pressure, and heart rate in a dose-dependent fashion. It is recommended to exercise caution when treating patients at higher risk of cardiovascular toxicities, particularly patients with known cardiovascular and cerebrovascular disease, preexisting hypertension, and patients with advanced age. Assess blood pressure and control hypertension before initiating treatment and monitor blood pressure regularly during treatment. Periodically reassess the need for continued therapy with solriamfetol and treat new-onset hypertension and exacerbations of preexisting hypertension according to clinical guidelines. If a patient experiences increases in blood pressure or heart rate that cannot be managed with dose reduction or other appropriate medical intervention, consider treatment discontinuation.


Solriamfetol (applies to Sunosi) psychiatric effects

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Anxiety/Stress

The use of solriamfetol may cause adverse psychiatric reactions, including anxiety, insomnia, and irritability. It is recommended to exercise caution when treating patients who have a history of psychosis or bipolar disorders. Observe patients treated with solriamfetol for the possible emergence or exacerbation of psychiatric symptoms and consider dose reduction or discontinuation of treatment.


Solriamfetol (applies to Sunosi) renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis, Cardiovascular Disease

The primary route of solriamfetol elimination is via urinary excretion. Dosage adjustment is not required for patients with mild renal impairment. Dosage adjustment is recommended for patients with moderate to severe renal impairment. Solriamfetol is not recommended for patients with end-stage renal disease. An average of 21% of solriamfetol is removed by hemodialysis. Patients with moderate or severe renal impairment may be at a higher risk of increases in cardiovascular adverse events and psychiatric symptoms because of the prolonged half-life.

Sunosi (solriamfetol) drug interactions

There are 81 drug interactions with Sunosi (solriamfetol)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.